Sterling Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Sterling Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.2K	Sell	3,621 -2,679	-43%	-$9.08K	﹤0.01%	2362
2025 Q4	$20.5K	Sell	6,300 -1,241	-16%	-$4.18K	﹤0.01%	2214
2025 Q3	$21.6K	Buy	7,541 +4,245	+129%	+$10.8K	﹤0.01%	2099
2025 Q2	$7.94K	Buy	3,296 +3,182	+2,791%	+$6.69K	﹤0.01%	2270
2025 Q1	$252	Hold	114	–	–	﹤0.01%	3059
2024 Q4	$621	Hold	114	–	–	﹤0.01%	3011
2024 Q3	$947	Buy	+114	New	+$985	﹤0.01%	2559

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sterling Capital Management's MRVI Position: Q1 2026 in Review

Sterling Capital Management reduced its Maravai LifeSciences (MRVI) stake by 43% in Q1 2026, selling an estimated $9.08K and leaving 3,621 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

Sterling Capital Management first reported a position in MRVI in Q3 2024 and has held it in 7 quarters since. The position peaked at $21.6K in Q3 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Sterling Capital Management held 3,621 shares of Maravai LifeSciences worth $10.2K as of Q1 2026.
Sterling Capital Management sold 2,679 Maravai LifeSciences shares in Q1 2026, an estimated $9.08K.
Maravai LifeSciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2362 holding.
Sterling Capital Management first reported a position in Maravai LifeSciences in Q3 2024 and has held it in 7 quarters since.
Sterling Capital Management's Maravai LifeSciences position peaked at $21.6K in Q3 2025.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.